CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Rituximabdrug
Likely dose
Rituximab 1000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00537290
NCT00537290Phase 2Completed
CompareCT.gov

A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome (RITAPS)

Hospital for Special Surgery, New York·interventional·Posted Oct 1, 2007·Updated Oct 31, 2017

In Brief

A Phase 2 clinical trial evaluating Rituximab for Antiphospholipid Syndrome. Completed, enrolled 19 participants across 1 site.

Detailed Summary

RITuximab AntiphosPholipid Syndrome (RITAPS) Study is designed to evaluate whether a medication called rituximab would reduce the signs and symptoms of antiphospholipid antibody (aPL) -related certain clinical problems.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAntiphospholipid Syndrome
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 1, 2007
Enrollment StartSep 1, 2007
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.8 years ago

Interventions

Rituximabdrug

Rituximab 1000mg IV on Days 0 and 15